| ²é¿´: 632 | »Ø¸´: 1 | |||
| µ±Ç°Ö÷ÌâÒѾ´æµµ¡£ | |||
zhp2hhľ³æ (ÕýʽдÊÖ)
|
[½»Á÷]
Ò½Ò©ÓªÏú³£ÓÃÓ¢ÎÄÏúÊÛÊõÓï
|
||
|
¡ñ POA£ºplan of Action Ðж¯¼Æ»® ¡ñ DA: Detailing AID Ðû´«µ¥Ò³ ¡ñ POP oint of Promotion ´ÙÏú½¹µã¹ã¸æ¡ñ BATS:Brand Awareness Tools Æ·ÅÆÌáʾÎï ¡ñSWOT:Strengths,Weaknesses,Opportunities,Threats ÓÅÊÆ¡¢ÈõÊÆ¡¢ »ú»á¡¢Íþв ¡ñ CSM:Core selling Message ºËÐÄ´ÙÏúÓï¾ä ¡ñ PDCA lan,Do,Check,Action ¼Æ»®£¬Ö´ÐУ¬¼ì²é£¬Ðж¯Ñ»·¡ñ PR ublic Relation ¹«¹²¹ØÏµ ¡ñ VIP:Very Important Person ÖØÒªÈËÎ¹ó±ö ¡ñ OLS:Opinion Ldaders ѧÊõ´øÍ·ÈË ¡ñ ADR:Adverse Trial Ò©Æ·²»Á¼·´Ó¦ ¡ñ CT:Clinical TrialÁÙ´²ÊÔÑé ¡ñ OGP:Outcome Guarantee ProgramÒ©Æ·ÁÙ´²Ð§¹ûÔÙÑéÖ¤ÊÔÑé ¡ñ GMP:Good Manufacture PracticeºÃµÄÒ©Æ·Éú²ú¹æ·¶ ¡ñ GCP:Good Clinical Trial Practice ºÃµÄÁÙ´²ÊÔÑ鹿·¶ ¡ñ Joint Call £º Ðͬ°Ý·Ã ¡ñ Coaching Call: ¸¨µ¼ÐÔ°Ý·Ã |
» ²ÂÄãϲ»¶
²ÄÁÏ¿¼Ñе÷¼Á
ÒѾÓÐ29È˻ظ´
297¹¤¿Æ£¬Çóµ÷¼Á?
ÒѾÓÐ10È˻ظ´
211±¾¿Æ²ÄÁÏ»¯¹¤Çóµ÷¼Á
ÒѾÓÐ19È˻ظ´
0831Ò»ÂÖµ÷¼Áʧ°ÜÇóÖú
ÒѾÓÐ10È˻ظ´
²ÄÁÏÏà¹Ø×¨Òµ344Çóµ÷¼ÁË«·Ç¹¤¿ÆÑ§Ð£»ò¿ÎÌâ×é
ÒѾÓÐ9È˻ظ´
Çóµ÷¼Á£¬985²ÄÁÏÓ뻯¹¤348·Ö
ÒѾÓÐ13È˻ظ´
085600²ÄÁÏÓ뻯¹¤349·ÖÇóµ÷¼Á
ÒѾÓÐ8È˻ظ´
Ò»Ö¾Ô¸ÖÐÄÏ´óѧ 0855 »úе 286 Çóµ÷¼Á
ÒѾÓÐ9È˻ظ´
Ò»Ö¾Ô¸085502£¬267·ÖÇóµ÷¼Á
ÒѾÓÐ15È˻ظ´
Ò»Ö¾Ô¸Õã´óÉúÎï325·ÖÇóµ÷¼Á
ÒѾÓÐ9È˻ظ´
» ±¾Ö÷ÌâÏà¹ØÉ̼ÒÍÆ¼ö: (ÎÒÒ²ÒªÔÚÕâÀïÍÆ¹ã)
1
|
2Â¥2007-02-22 12:22:50













oint of Promotion ´ÙÏú½¹µã¹ã¸æ
»Ø¸´´ËÂ¥